(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
John P. Perentesis, MD, FAAP Director, Division of Oncology and Cancer Programs
is a nationally recognized expert in the development of new therapies for pediatric cancers, leading new clinical trials through the Children’s Oncology Group, the NCI Phase I/Pilot Consortium, and the Department of Defense-funded Neurofibromatosis Consortium. His laboratory focuses on leukemia/lymphoma pharmacogenetics and has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells.
Director, Division of Oncology and Cancer Programs
Deb Kleisinger Endowed Chair of Novel Cancer Treatments
Executive Co-Director, Cancer and Blood Diseases Institute
Director, Leukemia / Lymphoma Program
Cincinnati Children's Principal Investigator, Children’s Oncology Group (COG)
Cincinnati Children's Principal Investigator, National Cancer Institute Pediatric Phase 1 Consortium
Professor, UC Department of Pediatrics
Acute myeloid leukemia; neuroblastoma; PNET / Ewing's sarcoma and osteosarcoma; new anticancer drug development; Phase I clinical trials
John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.
In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.
Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.
Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.
Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.
Michael J. Absalon, MD, PhD Member, Division of Oncology
focuses on developing new therapies and combinations of therapies for pediatric leukemias and lymphomas. He is currently investigating the therapeutic potential of combining the new targeted drug sorafenib with conventional chemotherapy for relapsed AML.
Member, Division of Oncology
Assistant Professor, UC Department of Pediatrics
Relapsed leukemia; lymphoma
BS: Lewis and Clark College, Portland, OR, 1987.
PhD: Massachusetts Institute of Technology, Cambridge, MA, 1994.
MD: Oregon Health Sciences University, Portland, OR, 1998.
Fellowship: St. Jude Children's Research Hospital, Memphis, TN, 2005.
Absalon MJ, Smith FO. Treatment strategies for pediatric acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jan;10(1):57-79. Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F. Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma.Pediatr Blood Cancer. 2008 Jun;50(6):1147-53.
Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin.Cell. 2005 Oct 7;123(1):49-63.
Absalon MJ, Harding CO, Fain DR, Li L, Mack KJ. Leigh syndrome in an infant due to mitochondrial DNA depletion. Pediatr Neurology. 2001; 24:60-63.
Denise M. Adams, MD Marjory J. Johnson Chair of Vascular Tumor Translational Research
is a nationally recognized expert on vascular anomalies with a keen interest in rare vascular tumors and life threatening malformations. She leads a clinical and translational research program to develop new therapies for these conditions and currently is the PI of a clinical study of sirolimus, a mTOR inhibitor, in the treatment of complicated vascular anomalies, the first trial of a new therapy for these conditions.
Marjory J. Johnson Chair of Vascular Tumor Translational Research
Medical Director, Hemangioma and Vascular Malformation Program
Fellowship Director, Hematology / Oncology
Quarmyne MO, Gupta A, Adams DM. Lymphangiosarcoma of the thorax and thoracic vertebrae in a 16-year-old girl. J Clin Oncol. 2012 Oct;30(29):294-8.
Haggstrom AN, Beaumont JL, Lai JS, Adams, DM, Drolet BA, Frieden IJ, Garzon MC, Holland KE, Horii KA, Lucky AW, Mancini AJ, Metry DW, Morel KD, Newell BD, Nopper AJ, Siegel D, Swigonski NL, Cella D, Chamlin SL. Measuring the severity of infantile hemangiomas: instrument development and reliability. Arch Dermatol. 2012 Feb;148(2):197-202.
Fadell MF 2nd, Jones BV, Adams DM. Prenatal diagnosis and postnatal follow-up of rapidly involuting congenital hemangioma (RICH).Pediatr Radiol. 2011 Aug;41(8):1057-60.
Maugans T, Sheridan RM, Adams D, Gupta A. Cutaneous vascular anomalies associated with neural tube defects: nomenclature and pathology revisited.Neurosurgery. 2011 Jul;69(1):112-8.
Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24.
Adams DM. Special considerations in vascular anomalies: hematologic management. Clin Plast Surg. 2011 Jan;38(1):153-60.
Duffy KJ, Runge-Samuelson C, Bayer ML, Friedland D, Sulman C, Chun R, Kerschner JE, Metry D, Adams D, Drolet BA. Association of hearing loss with PHACE syndrome. Arch Dermatol. 2010 Dec;146(12):1391-6. Drolet BA, Chamlin SL, Garzon MC, Adams D, Baselga E, Haggstrom AN, Holland KE, Horii KA, Juern A, Lucky AW, Mancini AJ, McCuaig C, Metry DW, Morel KD, Newell BD, Nopper AJ, Powell J, Frieden IJ. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin.J Pediatr. 2010 Nov;157(5):789-94.
Lomenick JP, Reifschneider KL, Lucky AW, Adams D, Azizkhan RG, Woo JG, Backeljauw PF. Prevalence of adrenal insufficiency following systemic glucocorticoid therapy in infants with hemangiomas. Arch Dermatol. 2009 Mar;145(3):262-6.
Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, Adams DM, Azizkhan RG. Spectrum of hepatic hemangiomas: management and outcome.J Pediatr Surg. 2009 Jan;44(1):125-33.
Karen C. Burns, MD, MS Director, Cancer Survivorship Center
conducts research on cancer survivorship and serious late effects of cancer treatment, including obesity, heart problems, fertility issues, increased risk of second cancers, and long-term outcomes of cancer survivors. She is also leading development of a fertility preservation program for children and adolescents undergoing chemotherapy as well as other unique medical and support services for adolescent and young adult cancer patients.
Director, Cancer Survivorship Center
BA: University of Pennsylvania, Philadelphia, PA, 1995.
MD: Temple University, Philadelphia, PA, 1999.
Residency: Pediatrics, St. Christopher's Hospital for Children in Philadelphia, PA, 2002.
MS: Medical College of Wisconsin, 2005.
Fellowship: Medical College of Wisconsin, 2005.
Burns K, Broudreau C, Panepinto J. Attitudes Regarding Fertility in Adolescent Females Diagnosed with Cancer. J Pediatr Hematol Oncol. 2006 Jun;28(6): 350-354.
Burns K and Camitta B. Pyrite or True Gold? Journal of Pediatric Hematology/Oncology. 2005 May;27(5): 244.
Lionel M.L. Chow, MD, PhD Member, Cancer Biology and Neural Tumors Program
Member, Cancer Biology and Neural Tumors Program
St. Baldrick’s Foundation Scholar
Sontag Foundation Distinguished Scientist
Lionel Chow, MD, PhD, received his medical and graduate degrees from McGill University in Montreal, Canada, where his research focused on the regulation of T-lymphocyte signaling by the intracellular tyrosine protein kinases Lck and Csk.
Following his clinical training in pediatrics and pediatric hematology / oncology at the Hospital for Sick Children in Toronto, Canada, he moved to St. Jude Children’s Research Hospital in Memphis, Tenn., to pursue his research interests.
Chow's research interests have been centered on glioblastoma multiforme, a particularly devastating form of cancer in adults and children. His work has resulted in the development of a number of novel and robust laboratory models for this disease. Using these models and interfacing with clinical trials in the Neuro-Oncology Program as well as those from national consortia such as the Children's Oncology Group (COG) and the Pediatric Brain Tumor Consortium (PBTC), Chow’s laboratory will continue research in this area with the goals of better understanding the origins of this form of cancer and improving patient outcomes.
PhD: McGill University, Montreal, Quebec, Canada, 1996.
MDCM: McGill University, Montreal, Quebec, Canada, 1997.
Residency: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 1997-2000.
Clinical Fellowship: The Hospital for Sick Children, University of Toronto, Toronto, Canada, 2000-2003.
Postdoctoral Fellowship: St. Jude Children’s Research Hospital, Memphis, TN, 2003-2009.Clinical Fellowship: St. Jude Children’s Research Hospital, Memphis TN, 2008-2009.
Certification: Pediatrics, 2000.
Hummel, TR, Chow, LML, Fouladi, M, and Franz, D. Pharmacotherapeutic management of pediatric astrocytomas: current and upcoming strategies. Pediatric Drugs 2013; 15:29-42.
Joshi, K, Banasavadi-Siddegowda, Y, Mo, X, Kim, SH, Mao, P, Kig, C, Nardini, D, Sobol, RW, Chow, LML, Kornblum, HI, Waclaw, R, Beullens, M, and Nakano, I. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013; 31:1051-1063.
Zhong, Y, Wan, Y-W, Pang, K, Chow, LML, and Liu, Z. Digital sorting of complex tissues for cell type-specific gene expression profiles. BMC Bioinformatics 2013; 14:89.
Rafalski, VA, Ho, PP, Brett, JO, Ucar, D, Dugas, JC, Pollina, EA, Chow, LML, Ibrahim, A, Baker, SJ, Barres, BA, Steinman, L, and Brunet, A. Expansion of oligodendrocyte progenitor cells upon SIRT1 inactivation in the adult brain. Nature Cell Biol. 2013; 15:614-624.
Wojton, J, Chu, Z, Mathsyaraja, H, Meisen, WH, Denton, N, Kwon, C-H, Chow, LML, Palascak, M, Franco, R, Bourdeau, T, Thornton, S, Ostrowski, MC, Kaur, B, and Qi, X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol. Ther. 2013; 21:1517-1525.
Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. Cooperativity within and among Pten, p53 and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19:305-316.
Lavado A, Lagutin O, Chow LML, Baker SJ, Oliver G. Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol. 2010;8:e1000460.
Cicero SA, Johnson D, Reyntjens S, Frase S, Connell S, Chow LML, Baker SJ, Sorrentino BP, Dyer MA. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A. 2009 Apr;106(16):6685-90.
Weber T, Corbett MK, Chow LML, Valentine MB, Baker SJ, Zuo J. Rapid cell-cycle reentry and cell death after acute inactivation of the retinoblastoma gene product in postnatal cochlear hair cells. Proc Natl Acad Sci U S A. 2008;105(2):781-5.
Chow LML, Zhang J, Baker SJ. Inducible Cre recombinase activity in mouse mature astrocytes and adult neural precursor cells. Transgenic Res. 2008;17(5):919-28.
Biplab Dasgupta, PhD, MS Member, Cancer Biology and Neural Tumors Program
Associate Professor, UC Department of Pediatrics
Biplab Dasgupta, PhD, MS, completed his doctorate in molecular biology and immunology at the Indian Institute of Chemical Biology, Calcutta, and a postdoctoral fellowship at Washington University School of Medicine, Saint Louis. Dr. Dasgupta came to Cincinnati Children's Hospital Medical Center in August 2009 as an assistant professor of pediatrics within the University of Cincinnati College of Medicine. He is interested in understanding how neural cell / stem cell metabolic and energy status is linked to cell cycle, lineage commitment, differentiation and tumorigenesis. His other interests include genetic, developmental, post-translational, tissue- and stimuli–specific regulation of the subunits that constitute the AMP kinase complex.
PhD: Indian Institute of Chemical Biology, Calcutta, 2003.
Postdoctoral Fellowship: Washington University School of Medicine, Saint Louis.
Xiaona Liu, Rishi Raj Chhipa and Biplab Dasgupta*. The Selective AMPK inhibitor Compound C is a potent AMPK-independent anti-glioma agent. Mol Cancer Ther. *Corresponding author. 2014 Mar:13(3):596-605
Xiaona Liu, Rishi Raj Chhipa, Shabnam Pooya, Matthew Wortman, Sara Yachishin, Ashish Kumar, Lionel Chow, Xuan Zhou, Ying Sun, Brian Quinn, Christopher McPherson, Ronald Warnick, Adi Kendler, Sailendra Giri, Jeroen Poels, Koennard Nogra, Benoit Viollet, Gregory A. Grabowski and Biplab Dasgupta*. Novel mechanisms of mTOR and cdc25c regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sc U S A. *Corresponding author. 2014 Jan 28;111(4):E435-44.
Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta B*. Direct inhibition of Retinoblastoma phosphorylation by Nimbolide causes cell cycle arrest and suppresses glioblastoma growth. Clin Cancer Research. 2014 Jan 1:20(1):199-212.
Dasgupta B, Ju JS, Sasaki Y, Liu X, Jung SR, Higashida K, Lindquist D, Milbrandt J. The AMPK beta2 subunit is required for energy homeostasis during metabolic stress. Mol Cell Biol. 2012; 32: 2837-48. Cover article. *Corresponding author.
Dasgupta B, Milbrandt J. AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev Cell. 2009 Feb;16(2):256-70.
Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A. 2007 Apr;24;104(17):7217-22.
Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2007 Oct 11;1(4):443-57.
Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005 Jun 8;25(23):5584-94.
Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005 Apr 1;65(7):2755-60.
Dasgupta B, Li W, Perry A, Gutmann DH. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 2005 Jan 1;65(1):236-45.
Jennifer A. Davis, DO
Instructor, UC Department of Pediatrics
Lymphatics; zebrafish xenograft model for tumor induced lymphangiogenesis; vascular tumors and malformations; development of animal models for targeted drug therapy.
BA: Samford University, Birmingham, AL.
DO: Kansas City University of Medicine and Biosciences, Kansas City, MO.
Pediatric Residency: University of Tennessee at Chattanooga T.C. Thompson Children’s Hospital, Chattanooga, TN.
Fellowship: Hematology, Oncology and Bone Marrow Transplant Fellowship, The Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Rachid Drissi, PhD
studies replicative senescence or cellular aging, believed to be a tumor suppressor mechanism by which normal cells limit cell proliferation to prevent genome instability and cancer. The long-term goal of their research program is to examine telomere disruption signaling to DNA damage pathway and senescence. They are also developing a combination therapy that includes telomere disruption to improve the outcome for children with brain tumors.
BS: University of Rouen, France, 1983.
MS: University of Rouen, France, 1984.
MS: University of Paris VI, France, 1988.
PhD: University of Paris VI, France, 1994.
Margol A, Robison N, Gnanachandran J, Hung LT, Kennedy R, Vali M, Muthugounder S, Dhall G, Finlay JL, Erdreich-Epstein A, Krieger MD, Drissi R, Fouladi M, Gilles FH, Judkins AR, Sposto R, Asgharzadeh S. Tumor Associated Macrophages in SHH Subgroup of Medulloblastomas. Clin Cancer Res. 2014 Oct 24.
Dorris K, Sobo M, Onar-Thomas A, Panditharatna E, Stevenson CB, Gardner SL, DeWire MD, Pierson CR, Rempel SA, Olshefski R, Goldman S, Miles L, Fouladi M, Drissi R*. Prognostic Significance of Telomere Maintenance Mechanisms in Pediatric High-Grade Gliomas. Journal of Neuro-Oncology. 2014 Jan 30. (*senior author)
Thompson PA, Drissi R*, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Weigel BJ, Blaney SM. A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase 1 Consortium Study (ADVL1112). Clin Cancer Res. 2013 Oct 4. (*biology chair)
Sturm D, Witt H, Hovestadt V, Quang DK, Jones DTW, Konermann C, Pfaff E, Sill M, Bender S, Kool M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Rizhova M, Tönjes M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald M, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Milde T, Witt O, Lindroth A, Schwartzentruber J, Faury D, Zakrzewska M, Zakrzewski K, Liberski PP, Zapatka M, Hauser P, Garami M, Klekner A, Bognar L, van Sluis P, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of glioblastoma. Cancer Cell. 2012;22:425-437.
Drissi R*, Bockhold CA, Wu J, Dome JS*. Telomere Shortening Alters the Kinetics of the DNA Damage Response after Ionizing Radiation in Human Cells. Cancer Prev Res. 2011;4(12):1973-1981. (*joint senior author)
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Shwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambroock PJ, Andreassen PR, Wiesmüller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011;39(17):7465-7476.
Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 2004 Sep 15;22(18):3790-7.
Drissi R*, Bakkenist CJ*, Wu J, Kastan MB, Dome JS. Disappearance of the telomere dysfunction-induced stress response in fully senescent cells. Cancer Res. 2004;64:3748-3752. (*equal contribution).
Drissi R, Zindy F, Roussel MF, Cleveland JL. c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem. 2001 Aug 10;276(32):29994-30001.
Stigger E, Drissi R, Lee SH. Functional analysis of human replication protein A in nucleotide excision repair. J Biol Chem. 1998 Apr 10;273(15):9337-43.
Maryam Fouladi, MD, MSc, FRCPC Medical Director, Neuro-Oncology Program
serves as chair for the CNS Tumor New Agents/Relapse Committee for the Children’s Oncology Group, and as member of the steering committee for the COG CNS Tumor Committee and the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair for active open clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Medical Director, Neuro-Oncology Program
Chair, Pediatric Brain Tumor Consortium Steering Committee
Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network
Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology / oncology fellowship training at the Hospital for Sick Children in Toronto, Canada. Dr. Fouladi then completed her neuro-oncology fellowship training at St. Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St. Jude before becoming a neuro-oncology faculty member in 2000. She served as the chair of the Phase I Committee at St. Jude.
Dr. Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children’s Oncology Group. She is a member of the steering committee for the COG CNS Tumor Committee as well as the Developmental Therapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair (through CERN, COG and the Pediatric Brain Tumor Consortium) for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
BS: Human Biology, University of Toronto, Toronto, Canada, 1987.
MD: University of Toronto, Toronto, Canada, 1991.
MSc: Institute of Medical Science, University of Toronto, Toronto, Canada, 2002.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Aug;33(6):e250-2.
Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: case report and review of the literature. J Neurooncol. 2011 Jul;103(3):759-64.
Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE, Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer. 2009 Jul 15;115(14):3243-53.
Shih C, Hale GA, Gronewold L, Tong X, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-Dose Chemotherapy with Autologous Stem Cell Rescue for Children with Recurrent Malignant Brain Tumors. Cancer. Mar 15;112(6):1345-53.
Fouladi M, Nicholson S, Zhou T, Laningham F, Helton K, et al. A Phase II Study of the Farnesyl Transferase Inhibitor, Tipifarnib, in Children with Recurrent or Progressive High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma: A Children’s Oncology Group Study. Cancer. 2007 Dec 1;110(11):2535-41.
Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt SL, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I Study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol. 2007 Oct 20;25(30):4806-12.
Morris B, Gajjar A, Okuma, J, Yutaka Y, Wallace D, Kun L, Merchant T, Fouladi M, Broniscer A, Robison L, Hudson M. Survival and Late Mortality in Long-term Survivors of Pediatric Central Nervous System Tumors. J Clin Oncol. 2007 Apr 20;25(12):1532-8.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicenter trial. Lancet Oncol. 2006 Oct;7(10):813-20. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.
Fouladi M, Blaney S, Young Poussaint T, Freeman B, McLendon R, Fuller C, Adesina A, Hancock M, Danks M, Ivy P, Stewart C, Gajjar A. A Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET) and atypical teratoid rhabdoid tumors (ATRT): A Pediatric Brain Tumor Consortium Study. Cancer. 2006 107:2291-2297.
Fouladi M. Histone deacetylase inhibitors. Cancer Invest. 2006 (5):521-7.
Merchant T, Fouladi M. Ependymoma: New therapeutic approaches including radiation and chemotherapy. J Neuro Oncol. 2006;3:287-99.
James I. Geller, MD Medical Director, Kidney and Liver Tumors Program
focuses on children and young adults affected by solid tumors. Dr. Geller's expertise is recognized internationally, as witnessed by his appointments to the Children's Oncology Group (COG) Renal Tumor, Liver Tumor, Retinoblastoma and Central Nervous System (Brain Tumor) Committees. Dr. Geller directs and spearheads local and national studies in these areas, with an emphasis on novel therapeutics.
Medical Director, Kidney and Liver Tumors Program
Co-Medical Director, Retinoblastoma Program
Associate Director, Global Cancer Programs
Developmental therapeutics; renal / liver / retinoblastoma / neuro-oncology
James I. Geller, MD, completed his undergraduate training at Dartmouth College, graduate medical training at the Sackler School of Medicine, residency training in pediatrics at New York Medical College and pediatric hematology / oncology training at St. Jude Children's Research Hospital. His current appointment is with Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of associate professor of pediatrics.
Dr. Geller's clinical and academic interests pertain to children and families affected by solid tumors, including brain tumors. Dr. Geller's expertise is recognized both nationally and internationally in the fields of retinoblastoma, renal tumors, liver tumors and brain tumors, as witnessed by his appointments to the Children's Oncology Group (COG) Rare / Retinoblastoma Committee as both a steering/voting member and as liaison to the COG Young Investigator Committee; the COG Renal Tumor Committee (RTC) as steering/voting member, RTC Sub-Committee chair of developmental therapeutics, and RTC liaison to both the COG Developmental Therapeutics Committee and the Pediatric Preclinical Testing Program Guidance Committee; and to the Central Nervous System (Brain Tumor) Committee as a voting member. Dr. Geller has been an invited speaker at numerous national and international meetings and symposia and spearheads both local and national clinical research initiatives in these areas, with an emphasis on finding new treatment options.
MD: Sackler School of Medicine, 1997.
Residency: New York Medical College, 2000.
Fellowship: St Jude Children's Research Hospital, 2004.
Certification: Pediatrics, 2000, 2007; Pediatric Hematology / Oncology, 2005.
Geller JI, Meyers AB, Towbin AJ, Serai S, Geller JI, Podberesky DJ. Characterization of pediatric liver lesions with gadoxetate disodium. Pediatr Radiol. 2011 Sep;41(9):1183-97.
Pressey JG, Wright JM, Geller JI, Joseph DB, Pressey CS, Kelly DR. Sirolimus therapy for fibromatosis and multifocal renal cell carcinoma in a child with tuberous sclerosis complex. Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7.
Cripe TP. Adenovirus gene therapy for pediatric cancers: shall we gather at the liver? Pediatr Blood Cancer. 2009 Aug;53(2):133-5.
Geller JI, Dome JS. Retroperitoneal lymph node dissection for pediatric renal cell carcinoma. Pediatr Blood Cancer. 2009 Mar;52(3):430.
Geller JI, Leslie ND, Yin H. Malignant Rhabdoid Tumor. eMedicine from WebMD. 2009 Dec. Available online.
Geller JI. Genetic stratification of Wilms tumor: is WT1 gene analysis ready for prime time? Cancer. 2008 Sep 1;113(5):893-6.
Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008 Apr 1;112(7):1607-16.
Geller JI, Dome JS. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer. 2006 Apr;46(4):527.
Geller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004 Oct 1;101(7):1575-83.
Adrienne M. Hammill, MD, PhD Member, Division of Oncology
conducts clinical research on hemangiomas and vascular malformations, focusing on development of new therapies for these conditions and new tools for assessing response to therapy, including novel imaging modalities.
Hemangiomas and vascular malformations; genetic predispositions to cancer
Dr. Adrienne M. Hammill is trained in pediatrics and hematology/oncology and is particularly interested in bringing new and/or better medical therapy options to the treatment of vascular anomalies. She is one of the medical physicians for the Hemangioma and Vascular Malformations team. She obtained her schooling at the University of Texas Southwestern, and completed her residency and fellowship here at Cincinnati Children’s Hospital Medical Center. She is a dedicated professional and strives to improve the treatment of those she cares for. Dr. Hammill has a special interest in Sturge Weber syndrome and due to her dedicated involvement, Cincinnati Children’s has been named a site for the brain vascular malformations consortium, which is a clinical research group funded by National Institutes of Health and the rare disease network. She was nominated as a finalist for The Making a Difference Award in 2013 through the Patient Advisory Council. This nomination for staff was for their efforts to improve the patient’s experience in terms of lives saved, errors caught, kindness shown, and battles fought. A Cincinnati Children’s patient nominated Dr. Adrienne Hammill for making her feel secure and talking to her one-on-one as a friend, not a doctor.
MD: University of Texas Southwestern Medical School, Dallas, TX, 2004.
PhD: University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, TX, 2004.
Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Fellowship: Cincinnati Children’s Hospital Medical Center.
Certification: Pediatrics, 2008.
Trent R. Hummel, MD
focuses on developing novel therapeutics to treat children with all central nervous system tumors including those with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas. Dr. Hummel is leading a national Phase 1 clinical trial investigating temozolomide in combination with vorinostat.
Neuro-oncology; CNS tumors in neurofibromatosis type 1 and 2 research interests: developing novel therapeutics in central nervous system tumors including those with very poor prognosis such as high-grade gliomas and diffuse intrinsic pontine gliomas.
Trent R. Hummel, MD, completed his graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. His current appointment is at Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of assistant professor of pediatrics.
Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC). Dr. Hummel focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.
BS: Eastern Mennonite University, Harrisburg, VA, 1997.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2001.
Residency: Children’s Hospital Medical Center of Akron, Akron, OH, 2004.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007; Research Fellow, Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, 2008.
Certification: American Board of Pediatrics, 2004; Pediatrics, 2004; Pediatric Hematology / Oncology, 2011.
Gass D, Dewire M, Chow L, Rose SR, Lawson S, Stevenson C, Pai AL, Jones B, Sutton M, Lane A, Pruitt D, Fouladi M, Hummel TR. Pediatric tectal plate gliomas: a review of clinical outcomes, endocrinopathies, and neuropsychological sequelae. J Neurooncol. 2015 Jan 13.
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D'Agostino McGowan L, Liu GT. Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol. 2014 May;75(5):799-800.
Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep;60(9):1452-7.
Hummel TR, Chow LM, Fouladi M, Franz D. Pharmacotherapeutic Management of Pediatric Gliomas: Current and Upcoming Strategies. Pediatric Drugs. 2012.
Hummel TR, Miles L, Mangano FT, Jones BV, Geller JI. Clinical heterogeneity of desmoplastic infantile ganglioglioma: a case series and literature review. J Pediatr Hematol Oncol. 2012 Aug;34(6):e232-6.
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu G. Visual outcomes in children with neurofibromatosis type 1–associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012 Jun;14(6):790-7.
Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7.
Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-Related Plexiform Neurofibroma to High Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90.
Hummel TR, Jessen WJ, Miller SC, Kluwe L, Mautner V, Wallace M, Lázaro C, Page G, Worley P, Aronow B, Schorry E, Ratner N. Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin. Clin Cancer Res. 2010 Oct 15;16(20):5048-57.
Hummel T, Hord J. Favorable Response to Soft Tissue Sarcoma Therapy in Adolescent with Embryonal Renal Sarcoma. Pediatr Blood Cancer. 2004 Jul; 43(1):70-2.
Jennifer L. Mangino, MD
has clinical and academic interests that pertain to children and young adults with leukemias and lymphomas, with a focus on clinical trials for patients with relapsed or refractory disease. She also has a special interest in adolescent and young adult oncology patients.
Leukemia; lymphoma; adolescent and young adult oncology patients.
Dr. Mangino earned her undergraduate degree in biochemistry and her medical degree from The Ohio State University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Children's Hospital of Philadelphia. She was awarded a National Cancer Center grant (2011-2013) for her post-fellowship research.
MD: The Ohio State University, Columbus, OH, 2004.
Residency: Pediatrics, Children's Memorial Hospital, Chicago, IL, 2007.
Fellowship: Children's Hospital of Philadelphia, Philadelphia, PA, 2011.
Certification: Pediatrics, 2007; Pediatric Hematology and Oncology, 2013.
Benjamin E. Mizukawa, MD
is trained in pediatric hematology/oncology with a research emphasis in leukemia biology and novel therapeutics. His work is focused on understanding the role of small Rho GTPases in myeloid leukemia development and progression, with the translational goal of identifying new targets for drug development.
Pediatric leukemia and lymphoma; investigation of the role of small Rho GTPases in leukemogenesis and leukemic stem cell biology and their potential as therapeutic targets in acute myeloid leukemia; development of xenograft models for use in testing novel therapeutics.
MD: University of Utah, Salt Lake City, UT, 2004.
Fellowship: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Certification: Pediatrics, 2008; Pediatric Hematology/Oncology, 2011.
Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013 Mar 21;121(12):e90-7.
Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC. The THPO/MPL/Bcl-xL pathway is essential for survival and self-renewal in human preleukemia induced by AML1-ETO. Blood. 2012;120(4):709-19.
Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA, Mulloy JC. Inhibition of Rac GTPase signaling and downstream pro-survival Bcl-2 proteins as combination targeted therapy in MLL-AF9 leukemia. Blood. 2011 118(19):5235-45.
Mizukawa B, George A, Pushkaran S, Weckbach L, Kalinyak K, Heubi JE, Kalfa TA. Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatr Blood Cancer. 2011 56(5): 840-2.
Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF, and IL-3. Leukemia. 2010; 24(10):1785-8.
Rajaram Nagarajan, MD, MS Associate Director, Oncology Clinical Operations
focuses on quality of life and outcomes following cancer therapy. His large collaborative studies involve the Children’s Oncology Group (COG), the Children's Cancer Survivor Study (CCSS) and National Children’s Hospital and Related Institutions (NACHRI) initiative. Dr. Nagarajan co-directs the Long-Term Follow-up Program which follows over 1,400 survivors, a unique program that follows “children” who are now well into adulthood.
Associate Director, Oncology Clinical Operations
Bone tumors; late effects of pediatric cancer therapy
BA: Pre-Medical Sciences, Lehigh University, Bethlehem, PA, 1991.
MD: Medical College of Pennsylvania, Philadelphia, PA, 1995.
Internship and Residency: Pediatrics, Medical College of Virginia, Richmond, VA, 1998.
Fellowship Training: Hematology / Oncology / BMT, University of Minnesota, Minneapolis, MN, 2002.
MS: Clinical Research, University of Minnesota, Minneapolis, MN, 2002.
Certifications: Pediatrics, Pediatric Hematology / Oncology.
Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, Yasui Y, Robison LL, Marina N. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the childhood cancer survivor study. Cancer. 2011 Feb 1;117(3):625-34.
Rayburg M, Towbin A, Yin H, Maugans T, Maurer B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. Pediatr Blood Cancer. 2009 Dec;53(6):1111-3.
Nagarajan R. Quality of life (QOL) in patients with osteosarcoma. Recent Results Cancer Res. 2009;179:339-44.
Nagarajan R, Mogil R, Neglia JP, Robison LL, Ness KK. Self-reported global function among adult survivors of childhood lower-extremity bone tumors: a report from the Childhood Cancer Survivor Study (CCSS). J Cancer Surviv. 2009 Mar;3(1):59-65.
Zebrack BJ, Zevon MA, Turk N, Nagarajan R, Whitton J, Robison LL, Zeltzer LK. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007 Jul;49(1):47-51.
Khan K, Schwarzenberg SJ, Sharp H, Jessurun J, Gulbahce HE, Defor T, Nagarajan R. Diagnostic endoscopy in children after hematopoietic stem cell transplantation. Gastrointest Endosc. Sep 2006;64(3):379-85.
Schultz KA, Ness KK, Nagarajan R, Steiner ME. Adnexal masses in infancy and childhood. Clinical Obstetrics and Gynecology. Sep 2006; 49(3):464-79.
Nagarajan R, Clohisy D, Weigel B. New paradigms for therapy for osteosarcoma. Curr Oncol Rep. 2005 Nov;7(6):410-4.
Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr. 2005;(34):72-6.
Spector LG, Ross JA, Nagarajan R. Epidemiology of bone and soft tissue sarcomas. In Pappo A (Ed.) Pediatric Bone and Soft Tissue Tumors. 1st ed. Berlin: Springer-Verlag, 2006.
Maureen M. O'Brien, MD, MS Associate Director, Leukemia / Lymphoma Program
is a clinical researcher developing new therapies for children, adolescents, and young adults with leukemia and lymphoma including combination of the mTOR inhibitor sirolimus with chemotherapy for patients with relapsed acute lymphoblastic leukemia. Her other research interests include improvements in the supportive care of patients with cancer, with a focus on identification of genetic risk factors and biomarkers for chemotherapy-related toxicity and infectious complications.
Associate Director, Leukemia / Lymphoma Program
MD: Harvard Medical School, Boston, MA, 2000.
Residency: Boston Combined Residency Program, Boston Children's Hospital and Boston Medical Center, Boston, MA, 2003.
Fellowship: Stanford University School of Medicine, Stanford, CA, 2007.
MS: Stanford University, Stanford, CA, 2008.
Certification: Pediatrics, 2003; Pediatric Hematology/Oncology, 2009.
Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther. 2010 Nov;9(11):2970-81.
O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 May;54(5):694-702.
O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010 Mar 1;28(7):1232-9.
Jeng MR, O’Brien M, Wong W, Zoland J, Lea J, Tang N, Glader B. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia. Haemophilia. 2009 Nov 15(6):1272-80.
Donaldson SS, O'Brien MM. Understanding the risk of second malignant tumors in children with Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):4-5.
O’Brien MM, Lee-Kim Y, George T, McClain K, Twist C, Jeng M. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis: case series and review of the literature. Pediatr Blood Cancer. 2008 Feb 50(2):381-3
O’Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children’s Oncology Group Study POG 9421. J Clin Oncol. 2008 Jan 26(3):414-420.
Christine L. Phillips, MD Member, Division of Oncology
is a clinical oncologist with a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics. Recent work has involved examining common genetic polymorphisms and their contribution to efficacy of therapy and risk for side effects in patients with acute myeloid leukemia.
Leukemia and lymphoma; leukemia pharmacogenetics; translational and clinical development of new drugs for high-risk and relapsed leukemias
Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.
Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.
MD: Indiana University School of Medicine, Indianapolis, IN, 2002.
Residency: Pediatrics, Children’s Memorial Hospital, Chicago, IL, 2005.
Fellowship: Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2010.
Certification: Pediatrics, 2005; Pediatric Hematology/Oncology, 2011.
Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with Melanotic Differentiation: Case Report and Review of the Literature. J Neurooncol. 2011 Jul;103(3):759-64.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 Polymorphism Increases Susceptibility to Childhood Acute Myeloid Leukemia. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Joseph G. Pressey, MD Director, Musculoskeletal Tumor Program
is the director of the musculoskeletal tumor program in the Cancer and Blood Diseases Institute. His primary interests include the translational and clinical aspects of childhood and young adult sarcomas. Dr. Pressey’s research focuses on the identification of novel therapies for high-risk and recurrent/refractory pediatric cancers and the conduct of early phase clinical trials.
Director, Musculoskeletal Tumor Program
Program Leader, Young Adult Oncology Center
Musculoskeletal tumors including rhabdomyosarcoma and other soft-tissue sarcomas; Ewing sarcoma; osteosarcoma; pediatric solid tumors; rare tumors including small cell carcinoma of the ovary.
Dr. Pressey graduated from the University of Georgia and the Medical College of Georgia before pursuing pediatrics residency training at Cincinnati Children’s Hospital Medical Center. He trained in pediatric hematology-oncology at the Children’s Hospital of Philadelphia where he developed a keen interest in pediatric sarcomas. He spent 11 years at the University of Alabama at Birmingham School of Medicine and Children’s Hospital of Alabama where he functioned as the principal investigator (PI) for the Children’s Oncology Group (COG) phase 1 and Pilot Consortium and the Sarcoma Alliance for Research through Collaboration (SARC).
Dr. Pressey joined the Cancer and Blood Diseases Institute at Cincinnati Children’s to direct the musculoskeletal tumor program. He is appointed clinical associate professor at the University of Cincinnati School of Medicine and functions as the Cincinnati Children’s Institutional PI for SARC. Dr. Pressey’s research is focused on the development of novel therapies for high-risk and recurrent/refractory solid tumors. Accordingly, he is developing a phase I trial for the COG phase I consortium and bench to bedside investigator initiated trials in collaboration with other investigators nationally.
MD: Medical College of Georgia, Augusta, GA, 1995.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1998.
Fellowship: Pediatric Hematology-Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 2001.
Certification: Pediatric Hematology-Oncology, 2002.
Kaylani SZ, Xu J, Srivastava RK, Kopelovich L, Pressey JG, Athar M. Rapamycin Targeting mTOR and Hedgehog Signaling Pathways Blocks Human Rhabdomyosarcoma Growth in Xenograft Murine Model. Biochem Biophys Res Commun. 2013 Jun 14;435(4):557-61.
Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WPD, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Bodour S, Prat J, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RBS, Cunliffe HE, Huntsman DG, Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations of SMARCA4. Nat Genetics. 2014 May;46(5):427-9.
Pressey JG, Kelly DR, Hawthorne HT. Successful treatment of preadolescents with small cell carcinoma of the ovary hypercalcemic type. J Pediatr Hematol Oncol. 2013 Oct;35(7):566-9.
Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY, Friedman GK. CD133 Marks a Myogenically Primitive Subpopulation in Rhabdomyosarcoma Cell Lines that are Relatively Chemoresistant but Sensitive to Mutant HSV. Pediatr Blood Cancer. 2013 Jan; 60(1):45-52.
Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG. Hedgehog Pathway Activity in Pediatric Embryonal Rhabdomyosarcoma and Undifferentiated Sarcoma: A Report from the Children’s Oncology Group. Pediatr Blood Cancer. 2011 Dec 1;57(6):930-8.
Pressey JG, Pressey CS, Kelly DR, Robinson G, Herron R, Wilson L, Kim H. 2D-Difference Gel Electrophoretic Proteomic Analysis of a Cell Culture Model of Alveolar Rhabdomyosarcoma. J Proteome Res. 2011 Feb 4;10(2):624-36.
Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets C, Kopelovich L, Athar M. Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res. 2010 Aug 15;70(16):6566-76.
Friedman GF, Pressey JG, Reddy AT, Markert JM, Gillespie GY. Herpes Simplex Virus Oncolytic Therapy for Pediatric Malignancies. Mol Ther. 2009 Jul;17(7):1125-35.
Siegel HJ, Pressey JG. Current Concepts in the Surgical and Medical Management of Osteosarcoma. Expert Rev Anticancer Ther. 2008 Aug;8(8):1257-69.
Womer RB, Pressey JG. Rhabdomyosarcoma and soft tissue sarcoma in childhood. Curr Opin Oncol. 2000 Jul ;12: 337-44.
Lisa M. Privette Vinnedge, PhD Director, Office of Postdoctoral Affairs
investigates the transcriptional regulation of cancer-associated genes and the downstream effects on signaling pathways and cell behaviors in breast cancer. The goal of her research is to understand the molecular drivers of breast cancer initiation and progression in order to improve treatment outcomes. She also conducts pre-clinical studies to both identify new cancer biomarkers and test novel therapeutics.
Director, Office of Postdoctoral Affairs
Breast cancer; gene expression; metastasis; cell cycle; DEK; oncogenes and tumor suppressors
BA: Miami University, Oxford, OH, 2002.
MS: University of Michigan, Ann Arbor, MI, 2004.
PhD: University of Michigan, Ann Arbor, MI, 2008.
Pease NA, Wise-Draper TM, Privette Vinnedge LM. Dissecting the potential interplay of DEK functions in inflammation and cancer. Journal of Oncology. 2015.
Privette Vinnedge LM, Benight N, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas J, Waltz SE, Wells SI. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor positive breast cancers. Oncogene. 2015 Apr 30;34(18):2325-36.
Privette Vinnedge LM, Kappes F, Nassar N, Wells SI. Stacking the DEK: from chromatin topology to cancer stem cells. Cell Cycle. 2013 Jan 1;12(1):51-66.
Privette Vinnedge LM, Wikenheiser-Brokamp KA, Ho S-M, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling. PLoS One. 2012;7(10):e46985.
Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI. The human DEK oncogene stimulates beta catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 2011 Jun 16;30(24):2741-52.
Gonzalez ME, Makarova O, Peterson EA, Privette LM, Petty EM. Up-regulation of SEPT9_v1 stabilizes c-Jun-N-terminal Kinase and contributes to its pro-proliferative activity in mammary epithelial cells. Cellular Signaling. 2009 Apr;21(4):477-487.
Privette LM, Petty EM. CHFR: a novel mitotic checkpoint protein and regulator of tumorigenesis. Translational Oncology. 2008 Jul;1(2):57-64.
Privette LM, Weier JF, Nguyen HN, Yu X, Petty EM. Loss of CHFR expression in mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia. 2008 Jul;10(7):643-652.
Gonzalez ME, Peterson EA, Privette LM, Loffreda-Wren JL, Kalikin LM, Petty EM. High SEPT9_v1 expression in human breast cancer cells is associated with oncogenic phenotypes. Cancer Research. 2007 Sep 15;67(18):8554-64.
Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM. Altered expression of the early mitotic checkpoint gene, CHFR, in breast cancers: Implications for tumor suppression. Cancer Research. 2007 Jul 1;67(13):6064-74.
Evaluating DEK as a Serum Biomarker and Novel Therapeutic Target in Head and Neck Cancer. HOPGA Division Pilot Grant. University of Cincinnati College of Medicine. Co-Principal Investigator. Aug 2015-Jul 2016.
Targeting the DEK oncogene using RNA nanoparticle technology as a novel cancer therapeutic. Collaborative Pilot Award, Center for Clinical and Translational Science, University of Kentucky and University of Cincinnati. Co-Principal Investigator. Aug 2015-Jul 2016.
Susan R. Rose, MD Member, Division of Endocrinology
investigates hypothalamic pituitary function and disorders of growth, puberty or thyroid hormone. She has special interest in the effects of neural injury on hypothalamic-pituitary function, such as after traumatic brain injury, cranial radiation, anoxia, iron overload.
Member, Division of Endocrinology
Neuro-endocrinology; hypothalamic-pituitary injury; growth disorders; puberty disorders; thyroid disorders; late effects of cancer
Susan Rose is professor in the Division of Endocrinology at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati. She has published over 100 review articles or chapters, and about 100 peer-reviewed articles. These include updating guidelines for care of congenital hypothyroidism and writing the chapter on thyroid for Fanaroff's and Avery's textbooks of neonatology. She’s served on the state newborn screening (NBS) committee in Tennessee. She is involved in long term follow up of newborn screening for CAH and congenital hypothyroidism with Region 4 and with the Federal Workgroup on NBS Standards.
She has clinical expertise and research interests in hypothalamic pituitary function, thyroid hormone disorders, and in disorders of growth or puberty. She has a special interest in the effects of central nervous system injury on hypothalamic-pituitary function. In addition, she has expertise and experience in evaluating the endocrine conditions associated with congenital bone marrow failure syndromes such as Fanconi anemia, Blackfan Diamond anemia, and Shwachman-Diamond syndrome. In addition, she is evaluating the endocrine consequences of hypothalamic-pituitary injury, including traumatic brain injury and injury from treatments for cancer, as well as comparing the relative efficacy of several treatments for precocious puberty. In this study, she will be developing growth curves specific to Fanconi Anemia, recognizing that healthy children with FA may not grow along the typical growth pattern of other healthy children.
MD: Case Western Reserve School of Medicine, 1980.
MEd: School Psychology, University of Dayton, 1972.
Residency: The Cleveland Clinic, 1983.
Fellowship: National Institutes of Health, 1986.
Certification: Pediatrics, 1985; Pediatric Endocrinology, 1986.
Auble BA, Makoroff K, Bollepalli S, Weis T, Colliers T, Khoury J, Rose SR. Hypopituitarism in pediatric survivors of inflicted traumatic brain injury. J Neurotrauma. 2014 Feb 15;31(4):321-6.
Myers KC, Rose SR, Rutter MM, Mehta PA, Cole T, Harris RE. Endocrine evaluation of children with and without Shwachman-Bodian-Diamond syndrome gene mutations and Shwachman-Diamond syndrome. J Pediatr. 2013 Jun;162(6):1235-40.
Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012 Dec;22(12):1046-56.
Rose SR, Myers K, Rutter MM, Mueller R, Khuory JC, Mehta PA, Harris RE, Davies SM. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012 Oct;59(4):690-6.
Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011 Dec 20;29(36):4776-80.
Kaulfers AM, Backeljauw PF, Reifschneider K, Blum S, Michaud L, Weiss M, Rose SR. Endocrine dysfunction following traumatic brain injury in children. J Pediatr. 2010 Dec;157(6): 894-9.
Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr. 2010 Oct;157(4):662-7.
Slaughter JL, Meinzen-Derr J, Rose SR, Leslie ND, Chandrasekar R, Linard SM, Akinbi HT. The effects of gestational age and birth weight on false-positive newborn screening rates. Pediatrics. 2010 Nov;126(5):910-6.
Kazlauskaite R, Evans AT, Villabona CV, Abdu TAM, Ambrosi B, Atkinson AB, Choi CH, Courtney CH, Gonc EN, Maghnie M, Oelkers W, Rose SR, Soule SG, Tordjman K, Consortium for evaluation of corticotropin test in hypothalamic-pituitary insufficiency. Corticotropin tests for hypothalamic-pituitary adrenal insufficiency: A metaanalysis. J Clin Endocrinol Metab. 2008 Nov;93(11):4245-53.
Rose SR. Pharmacologic and physiologic regulators of the nocturnal TSH surge; A clinical research center study. Recent Advances and Research Updates. ISSN 0972-4699, 2007; 8:219-29.
William L. Seibel, PhD
is a synthetic medicinal chemist with over 20 years of industrial and academic experience in the discovery of biologically active molecules and optimization toward human clinical trials. His lab provides advice in lead discovery, hit-to-lead and lead optimization approaches, including medicinal chemistry, computational chemistry and screening.
Small molecule drug discovery
William Seibel, PhD, completed his doctorate in chemistry at Harvard University. He then worked for 19 years in various positions at Procter & Gamble Pharmaceuticals, managing migraine and antimicrobials drug discovery groups as well as technology groups in computational, modeling, structural biology and combinatorial chemistry. He then served as head of the University of Cincinnati College of Medicine’s Compound Library and Cheminformatics group and as project manager for the Drug Discovery Center, both of which continue through his Cincinnati Children's Hospital Medical Center appointment. His interests are in working with various collaborators to find the most efficient and effective approaches to identify biologically active small molecules, and advance these leads to clinical candidate status.
Fells JI, Lee SC, Fujiwara Y, Norman DD, Lim KG, Tsukahara R, Liu J, Patil R, Miller DD, Kirby RJ, Nelson S, Seibel W, Papoian R, Parrill AL, Baker DL, Bittman R, Tigyi G. Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface. Mol Pharmacol. 2013 Sep;84(3):415-24.
Cash JN, Angerman EB, Kirby RJ, Merck L, Seibel WL, Wortman MD, Papoian R, Nelson S, Thompson TB. Development of a small-molecule screening method for inhibitors of cellular response to myostatin and activin A. J Biomol Screen. 2013 Aug;18(7):837-44.
Panmanee W, Taylor D, Shea CJ, Tang H, Nelson S, Seibel W, Papoian R, Kramer R, Hassett DJ, Lamkin TJ. High-throughput screening for small-molecule inhibitors of Staphylococcus epidermidis RP62a biofilms. J Biomol Screen. 2013 Aug;18(7):820-9.
Shang X, Marchioni F, Evelyn CR, Sipes N, Zhou X, Seibel W, Wortman M, Zheng Y. Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60.
Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek-Willemsen M, Duhr S, Seibel W, Wortman M, Zheng Y. Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol. 2012 Jun 22;19(6):699-710.
Tan Z, Wortman M, Dillehay KL, Seibel WL, Evelyn CR, Smith SJ, Malkas LH, Zheng Y, Lu S, Dong Z. Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth. Mol Pharmacol. 2012 Jun;81(6):811-9.
Bosco EE, Kumar S, Marchioni F, Biesiada J, Kordos M, Szczur K, Meller J, Seibel W, Mizrahi A, Pick E, Filippi MD, Zheng Y. Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation. Chem Biol. 2012 Feb 24;19(2):228-42.
Barger JF, Gallo CA, Torni KA, Merk L, Seibel WL, Nelson S, Plas DR. Identification of Akt-selective cytotoxic compounds that enhance cytotoxic responses to rapamycin. Cancer Biol Ther. 2010 Dec 15;10(12):1256-61.
Rathore R, Pribil P, Corr JJ, Seibel WL, Evdokimov A, Greis KD. Multiplex enzyme assays and inhibitor screening by mass spectrometry. J Biomol Screen. 2010 Sep;15(8):1001-7.
Rathore R, Corr JJ, Lebre DT, Seibel WL, Greis KD. Extending matrix-assisted laser desorption/ionization triple quadrupole mass spectrometry enzyme screening assays to targets with small molecule substrates. Rapid Commun Mass Spectrom. 2009 Oct 30;23(20):3293-300.
Brian K. Turpin, DO
Brian K. Turpin, DO, completed his undergraduate training at the University of Missouri, graduate medical training at the Kansas City University of Medicine and Biosciences, and pediatric residency and hematology / oncology fellowship at Cincinnati Children’s Hospital Medical Center where he served as co-chief fellow.
Dr. Turpin’s clinical and academic interests pertain to children and young adults with solid tumors, particularly sarcomas and neuroblastomas, with a research focus on the development of new drugs and clinical trials for patients with relapsed cancer.
DO: Kansas City University of Medicine and Biosciences.
Residency: Pediatrics, Cincinnati Children’s Hospital Medical Center.
Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cancer and Blood Diseases Institute.
Trout A, Sharp S, Turpin B, Zhang B, Gelfand M. Optimizing the interval between G-CSF therapy and F18 FDG-PET imaging in children and young adult patients receiving chemotherapy for sarcoma. Pediatric Radiology. 2015 Jul;45(7):1001-6.
Andersson C, Kvist PH, McElhinney K, Baylis R, Gram LK, Pelzer H, Lauritzen B, Holm TL, Hogan S, Wu D, Turpin B, Miller W, Palumbo JS. Factor XIII Transglutaminase Supports the Resolution of Mucosal Damage in Experimental Colitis. PLoS One. 2015 Jun 22;10(6):e0128113.
Turpin*, Whitney Miller*, Leah Rosenfeldt, Keith Kombrinck, Matthew J. Flick, Kris A. Steinbrecher, Eleana Harmel-Laws, Eric S. Mullins, Maureen Shaw, David P. Witte, Alexey Revenko, Brett Monia, Joseph S. Palumbo. (* signifies equal contributors). Thrombin drives tumorigenesis in colitis-associated colon cancer. Cancer Res. 2014 Jun 1;74(11):3020-30.
Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J. Pilot Study of Vincristine, Oral Irinotecan, and Temozolomide (VOIT Regimen) Combined with Bevacizumab in Pediatric Patients with Recurrent Solid Tumors or Brain Tumors.Pediatr Blood Cancer. 2013 Apr 29.
Turpin BK, Morris VR, Lemen L, Weiss BD, Gelfand MJ. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.Health Phys. 2013 Feb; 104(2 Suppl 1):S43-6.
Trehan I, Turpin BK. Neonatal respiratory distress due to bilateral dacrocystoceles. J Pediatr. 2008 Sep;153(3):438.
Turpin B, Tobias JD. Perioperative management of a child with short-chain acyl-CoA dehydrogenase deficiency. Paediatr Anaesth. 2005 Sep;15(9):771-7.
Cogar BD, Groshong TD, Turpin BK, Guajardo JR. Chylothorax in Henoch-Schonlein purpura: a case report and review of the literature. Pediatr Pulmonol. 2005 Jun;39(6):563-7.
Brian D. Weiss, MD Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute
focuses on new approaches to treat high-risk neuroblastoma, including novel ways to use 131I-MIBG therapy, and on targeted agents for neurofibromatosis type 1-related tumors and malignancies. In addition, he is researching methods and processes to ensure error-free delivery of therapy.
Associate Director for Safety and Compliance, Cancer and Blood Diseases Institute
Associate Director of Clinical Research, Division of Oncology
Cincinnati Children's Principal Investigator, New Approaches to Neuroblastoma Therapy Consortium
Medical Director, Neuroblastoma Program
MD: Northwestern University Medical School, Chicago, IL, 1993.
Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.
Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.
Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007.
Hummel T, Anyane-Yeboa A, Mo J, Towbin A, Weiss B. Response of NF1-related plexiform neurofibroma to High-Dose Carboplatin. Pediatr Blood Cancer. 2011 Mar;56(3):488-90.
Weiss B, Geiger H, Davies SM. Possible leukemogenic potential of temozolomide. Pediatr Blood Cancer. 2009 Apr;52(4):553.
Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009 Mar;33(3):355-62.
Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5418-25.
Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006 Apr 1;107(7):3010-1.
Weiss B and Shannon K. Preliminary Examples of Preclinical Trials. In Mouse Models of Cancer, Eric Holland (Ed). Wiley-Liss, 2004.
Susanne Wells, PhD Director, Epithelial Carcinogenesis and Stem Cell Program
Director, Epithelial Carcinogenesis and Stem Cell Program
Squamous cell carcinoma; mechanisms by which the HPV oncogenes subvert the host cell machinery to promote abnormal cell growth and cancer; role of specific cellular HPV targets in viral replication and cellular transformation
Visit the Wells Lab.
Susanne Wells graduated from the University of Konstanz, Germany, with a degree in biology. She completed her PhD in molecular biology at the State University of Stony Brook, NY, and her postdoctoral fellowship at Harvard Medical School, MA. Dr. Wells moved to Cincinnati Children's Hospital Medical Center in 2002 to study human papillomavirus infection and associated carcinogenesis.
Bahassi M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ. Rixe O. A patient-derived somatic mutation in the epidural growth factor ligand-binding domain confers increased sensitivity to cetuximab in heck and neck cancer. European J Cancer. 2013 Jul:49(10):2345-55.
Privette Vinnedge LM, Ho SM. Wikenheiser-Brokamp KA, Wells SI. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer. PLoS One. 2012;7(10):e46985.
Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Butsch Kovacic M, Wikenheiser-Brokamp KA, Wells SI. The Fanconi anemia pathway limits human papillomavirus replication. J Virol. 2012 Aug;86(15);8131-8.
Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI, Future directions and treatment strategies for head and neck squamous cell carcinomas. Transl Res. 2012 Sep;160(3):167-77.
Morrison MA, Morreale RJ, Akunuru S, Kofron M, Zheng Y, Wells SI. Targeting the human papillomavirus E6 and E7 oncogenes through expression of the BPV1 E2 protein stimulates cellular motility. J Virol. 2011 Oct;85(20):10487-98.
Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE, Filipovich AH, Kovacic MB, Wells SI, Mehta PA. Impaired immune function in children with Fanconi anaemia. Br J Haematol. 2011 Jul;154(2):234-40.
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmuller L, Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucl Acids Res. 2011 Sep 1;39(17):7465-76.
Privette Vinnedge LM, McClaine R, Wagh PK, Wikenheiser-Brokamp KA, Waltz SE, Wells SI. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer. Oncogene. 2011 Jun 16;30:2741-52.
Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Toile K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011 Feb 3;470(733):105-9.
Meyer SE, Peace BE, Bahassi el M, Kavanaugh GM, Wagh PK, Robbins SB, Yin M,Wells SI, Zinser GM, Stambrook PJ, Waltz SE. Chk2*1100delC Acts in synergy with the Ron receptor tyrosine kinase to accelerate mammary tumorigenesis in mice. Cancer Lett. 2010 Oct 28;296(2):186-93.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center